Emma Svennberg

Title: **Innovative Contributions of Emma Svennberg in Cardiac Healthcare**

Introduction

Emma Svennberg, located in Djursholm, Sweden, is a prominent inventor making significant strides in the field of cardiac healthcare. With a focus on diagnosing atrial fibrillation, Emma's innovative approach has the potential to enhance patient outcomes, particularly in the elderly population. She holds a patent that exemplifies her commitment to advancing medical technology and diagnostics.

Latest Patents

Emma Svennberg is credited with one patent: an **algorithm of NTproBNP and handheld ECG to detect arrhythmia in an elderly population**. This patent outlines a method for diagnosing whether a subject, without any known history of atrial fibrillation, is experiencing this condition. The steps involved in her method include determining the amount of a BNP-type peptide in a sample from the subject, comparing this amount to a reference, and assessing intermittent ECG recordings using a handheld device over a minimum duration of one week. This innovative solution is pivotal in early detection and management of atrial fibrillation.

Career Highlights

Emma is currently employed at Roche Diagnostics Operations, Inc., where she contributes her expertise in the development of diagnostic technologies. Her work focuses on improving diagnostic processes and making cardiac care more accessible, particularly for elderly patients. Emma's efforts align with Roche's mission to advance healthcare solutions through innovative medical technology.

Collaborations

Throughout her career, Emma has collaborated with esteemed colleagues, including Mathias Emil Egermark and Edelgard Anna Kaiser. These partnerships are crucial for fostering innovation and sharing knowledge, ultimately leading to the development of cutting-edge healthcare solutions. The synergy among these professionals enhances the impact of their collective work in the medical field.

Conclusion

Emma Svennberg's contributions to cardiac healthcare through her patent and collaborative efforts at Roche Diagnostics Operations, Inc. showcase her dedication to enhancing patient care. Her innovative methods have the potential to revolutionize the way atrial fibrillation is diagnosed, particularly in vulnerable populations. Emma continues to inspire future generations of inventors and healthcare professionals committed to advancing medical technology and improving lives.